argenx SEARGX -1.97%78 Days Payable is 417.99 as of Mar. 2026, which is 27% below its 10-year median of 572.66. GuruFocus rates ARGX with a GF Score™ of 78/100 and a GF Value™ of $1,395.78 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 704 Biotechnology companies, argenx SE ranks better than 74.15% on this metric.
argenx SE's average Accounts Payable for the
three
months ended in Mar. 2026 was $554 Mil. argenx SE's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $121 Mil.
Hence, argenx SE's Days Payable for the
three
months ended in Mar. 2026 was 417.99.
The historical rank and industry rank for argenx SE's Days Payable or its related term are showing as below:
ARGX'
s Days Payable Range Over the Past 10 Years
Min: 364.04 Med: 572.66 Max: 2384.36
Current: 364.04
During the past 13 years, argenx SE's highest Days Payable was 2384.36. The lowest was 364.04. And the median was 572.66.
ARGX's Days Payable is ranked better than 74.15% of 704
companies
in the Biotechnology industry
Industry Median: 113.56
vs ARGX: 364.04
argenx SE's Days Payable
increased
from Mar. 2025 (385.53) to Mar. 2026 (417.99).
It may suggest that argenx SEdelayed paying its suppliers.
argenx SE Days Payable Related Terms
argenx SE Days Payable Historical Data
* Premium members only.
The historical data trend for argenx SE's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, argenx SE's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Days Payable distribution charts can be found below:
* The bar in red indicates where argenx SE's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
argenx SE's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a Days Payable of 417.99 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on argenx SE and its competitors. This is 27% below median its historical median of 572.66. Over the past decade, argenx SE's Days Payable has ranged from 364.04 to 2,384.36. According to the industry distribution chart, argenx SE ranks #182 out of 704 companies in the Biotechnology industry, placing it in the top 25.9%.
Is argenx SE's Days Payable too high?
argenx SE's current Days Payable of 417.99 is 27% below median its 10-year median of 572.66. Over the past 10 years, this metric has ranged from a low of 364.04 to a high of 2,384.36. The Biotechnology industry median Days Payable is 113.56. argenx SE's value of 417.99 is 268.1% above this industry median. Based on the distribution chart, argenx SE ranks #182 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #182 out of 704 companies for Days Payable. This puts argenx SE in the upper half of its industry. The industry median Days Payable is 113.56. argenx SE's value of 417.99 is 268.1% above this benchmark. Historically, argenx SE's own Days Payable has ranged from 364.04 to 2,384.36 over the past decade. While the company's 10-year median is 572.66 vs. the industry median of 113.56, argenx SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current Days Payable of 417.99 is 268.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current Days Payable is 417.99, which is 27% below median its own 10-year median of 572.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,395.78, compared to a current price of $909.50 — trading 34.8% below its estimated fair value. The current Days Payable is 417.99, which is 27% below median its 10-year median of 572.66 and 268.1% above the Biotechnology industry median of 113.56. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For argenx SE (ARGX), the current Days Payable is 417.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $909.50 is trading 34.8% below its estimated GF Value™ of $1,395.78.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
Days Payable: 417.99 (27% below median its 10-year median of 572.66)
GF Value™: $1,395.78 vs. price of $909.50 (34.8% below fair value)
Industry Position: 268.1% above the Biotechnology median (#182 of 704)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for ARGX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
